# A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

> **NCT05600309** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 94 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** favezelimab/pembrolizumab
- **DRUG:** regorafenib
- **DRUG:** TAS-102

## Key facts

- **NCT ID:** NCT05600309
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-06-14
- **Primary completion:** 2024-08-15
- **Final completion:** 2025-02-21
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05600309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05600309, "A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05600309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*